Grifols prepares IPO of its US Biopharma business

Grifols Strategy Committee has proposed and the Board of Directors has approved the IPO on the U.S. stock market of a portion of the shares of Grifols U.S. Biopharma business. The proposed transaction follows the self-sufficiency programs launched across its Biopharma business units and will be subject to market conditions as well as applicable legal and regulatory requirements. If the transaction is successfully completed Grifols would float a minority stake in its U.S. Biopharma business. The parent company Grifols S.A. would maintain its listing in Spain and would retain control of the U.S. business. The proposed IPO is intended to raise capital to support the company's strategic priorities including debt reduction and investment in growth across key markets. Following the proposed IPO the Grifols U.S. Biopharma business will have its own Board of Directors dedicated leadership team and corporate governance structure. This structure will allow the company to operate with a clear strategic focus tailored governance and the agility needed to compete and grow as a U.S. listed company. This positioning aligns with investor interest in a pure-play U.S. plasma company and a simplified capital structure post-IPO. The sale of a minority stake of its U.S. Biopharma business Grifols is the largest player in the U.S. plasma market where it operates nearly 300 donation centers across 40 states and has major industrial facilities in California and North Carolina employing more than 14,000 people across the United States. The U.S. Biopharma business operates in the world's leading plasma market which supplies more than 60 percent of global plasma worldwide and continues to show strong structural demand.